Literature DB >> 7576068

From defined human tumor antigens to effective immunization?

T Boon1, T F Gajewski, P G Coulie.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7576068     DOI: 10.1016/0167-5699(95)80149-9

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


× No keyword cloud information.
  21 in total

Review 1.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

2.  Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.

Authors:  T Asai; W J Storkus; T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

3.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

4.  HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis.

Authors:  José A Campillo; Jorge A Martínez-Escribano; Manuel Muro; Rosa Moya-Quiles; Luis A Marín; Olga Montes-Ares; Natalia Guerra; Paloma Sánchez-Pedreño; José F Frías; José A Lozano; Ana M García-Alonso; M Rocío Alvarez-López
Journal:  Immunogenetics       Date:  2005-12-20       Impact factor: 2.846

Review 5.  The new vaccines: building viruses that elicit antitumor immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

6.  Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells.

Authors:  J Magarian-Blander; R P Hughey; C Kinlough; P A Poland; O J Finn
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

7.  Signals from lymphocytes in colon cancer.

Authors:  R Kiessling
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

8.  Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.

Authors:  Amanda J Vandeveer; Jonathan K Fallon; Robert Tighe; Helen Sabzevari; Jeffrey Schlom; John W Greiner
Journal:  Cancer Immunol Res       Date:  2016-02-26       Impact factor: 11.151

Review 9.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

Review 10.  Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.

Authors:  Chrisann Kyi; Michael A Postow
Journal:  Immunotherapy       Date:  2016-06       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.